ASCO:
Astex Pharma $ASTX will present phase 1 results for their HSP90 inhibitor candidate AT13387 - abstracts will be released May 15th, so stay tuned. There will also be several studies involving DACOGEN (decitabine) but none that are company-sponsored and there will not be development or regulatory filings of DACOGEN in any other indications.
1q-2012 partner updates:
Keep reading for updates regarding 1q-2012 earnings reports from big pharma partners and competitors of ASTX: Johnson & Johnson, Eisai, and Celgene.
Astex Pharma $ASTX will present phase 1 results for their HSP90 inhibitor candidate AT13387 - abstracts will be released May 15th, so stay tuned. There will also be several studies involving DACOGEN (decitabine) but none that are company-sponsored and there will not be development or regulatory filings of DACOGEN in any other indications.
1q-2012 partner updates:
Keep reading for updates regarding 1q-2012 earnings reports from big pharma partners and competitors of ASTX: Johnson & Johnson, Eisai, and Celgene.
RSS Feed
